Background {#Sec1}
==========

Approximately 30,000 cardiac procedures are performed each year in the United Kingdom, and it is estimated that approximately 10% of all blood supplied by the National Blood Service is used during these procedures. Bleeding after cardiac surgery that requires blood transfusion is associated with significant morbidity and mortality, resulting in substantial costs to healthcare systems \[[@CR1]\]. The national comparative audit in the United Kingdom in 2011, which incorporated data from 66% of all UK cardiac centres, showed that the overall blood transfusion rate was high across all procedures, with fresh frozen plasma (FFP) being administered in over 20% of patients undergoing valve replacement or repair surgeries and in 30% of patients undergoing combined coronary artery bypass graft + valve repair/replacement surgeries \[[@CR2]\].

FFP is the accepted standard treatment for replacement of clotting factors in bleeding patients undergoing cardiac surgery; yet, in a recent Cochrane review only 1 study out of 14 trials (*n* = 738 participants) identified has evaluated the efficacy of FFP in bleeding patients, and this was underpowered to determine outcomes in mortality \[[@CR3]\]. Taking into consideration that blood transfusion is not without risks, other haemostatic agents, such as prothrombin complex concentrate (PCC), are being explored by clinicians for management of bleeding, including in the peri-operative phase for patients undergoing cardiac surgery. Potential advantages of PCC over FFP include increased concentration of clotting factors leading to faster and more sustained reversal of coagulopathy, improved ease and speed of administration, reduced fluid volume (20--40 ml compared with up to 1000 ml with FFP), and reduced incidence of immunomodulatory side effects.

However, to date there have been no randomised controlled trials (RCT) that have compared the clinical efficacy and safety of PCC versus FFP in bleeding cardiac surgery patients who are not taking vitamin K antagonists (e.g., warfarin), and this was highlighted in a recent systematic review \[[@CR4]\]. Several observational studies have demonstrated that PCC is safe in this setting and that its administration is associated with reduced blood transfusion requirements, albeit with no difference in other outcomes \[[@CR5], [@CR6]\]. However, clinical equipoise and the lack of high-quality evidence means that an RCT is required to determine how PCC compares with FFP. Prior to such a trial, a pilot study is required to determine if a large-scale RCT is possible, and this is the hypothesis of our single-centre RCT.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

The study design is a single-centre (Barts Health NHS Trust), open-label, non-blinded, pragmatic, pilot RCT (see Fig. [1](#Fig1){ref-type="fig"} for study flowchart). Fig. 1Study flowchart

Aim and objectives {#Sec4}
------------------

The aim of this study is to determine if it is feasible to deliver a large trial in the future that will compare FFP versus PCC in cardiac surgery patients who are bleeding within 24 h of surgery.

### Primary objective {#Sec5}

The primary objective is to evaluate the recruitment rate, defined as the proportion of subjects who consent to the study (of all those eligible) and receive the intervention.

### Secondary objectives {#Sec6}

The following are secondary objectives of this study: Assess the delivery of different components of the trial, protocol compliance and violation, and the ability to collect outcome dataCompare the impact of FFP and PCC on the haemostatic capacity of bleeding patients through the use of standard clotting tests and other global clotting testsObtain input from patients, members of the public and healthcare professionals on the design/running of the large trial, as well as identify the most important primary/secondary outcomes for the larger trial

### Primary outcome {#Sec7}

The primary outcome will be the proportion of participants who receive the intervention within 24 h of surgery, out of all eligible participants.

### Secondary endpoints {#Sec8}

The secondary endpoints of the study are as follows: Time to administration of study drug (PCC) or control (FFP) to patient, defined as time in minutes from telephoning laboratory to first administration to patientProportion of patients for whom clinical outcome data were collected up to 90 days, or death, whichever occur firstProportion of patients who consent and are randomised within 24 h of surgeryProportion of patients who consent and are not randomised within 24 h of surgeryProportion of patients for whom timing of administration and completion of intervention(s) are documentedProportion of patients in whom there is protocol adherence and protocol violationProportion of patients who do not consent to intervention but agree to consenting of their de-identified data for up to 24 h after surgeryObtain data on event rates in both groups to help estimate the sample size for the large trial. Event rates will be assessed at 24 h and 7, 14, 21 and 30 days, or upon discharge or death, whichever is first. Clinical outcomes assessed at these time points include those described under 'Study assessment', such as total days in intensive care unit, any organ failure, thrombosis, acute transfusion reaction, infections, duration of organ support and mortality.

Study population {#Sec9}
----------------

A total of 50 patients will be randomised over a 15-month period, with follow-up at 90 days or death, whichever occurs first. Consent will be obtained from all patients prior to participation in the trial.

### Inclusion criteria {#Sec10}

The study will include adult patients (aged \> 18 years) who are able to give consent and undergoing elective or non-elective cardiac surgery, excluding procedures listed below under 'Exclusion criteria'.

### Exclusion criteria {#Sec11}

Exclusion criteria are inability to consent; patients refusing blood transfusion for any reason; first time isolated coronary artery bypass graft; first time isolated aortic valve replacement (excluding active endocarditis); thoraco-abdominal surgeries; minor surgeries that do not involve cardiopulmonary bypass; use of warfarin within 4 days; use of direct oral anticoagulants (i.e., dabigatran, rivaroxaban, apixaban or edoxaban) within 48 h or 72 h, depending on estimated glomerular filtration rate; inherited bleeding disorder; pregnancy; known or suspected allergy to FFP, octaplasLG (Octapharma, Lachen, Switzerland) or PCC; known or suspected allergy to heparin, sodium citrate dihydrate, sodium dihydrogen phosphate dihydrate and glycine; history of heparin-induced thrombocytopenia; immunoglobulin A (IgA) deficiency with known antibodies against IgA; documented venous thromboembolism in the last 3 months; documented antiphospholipid syndrome; severe protein S deficiency; and participation in another clinical trial where the patient has received an investigational medicinal product in the last 3 months.

For women of childbearing age (\< 50 years old) a urine pregnancy test will be performed for eligibility purposes. There will be no other study-specific screening procedures.

To determine the bleeding rate, routine clinical data will also be collected for up to 24 h for (1) eligible participants who have consented to take part in the study but are not randomised because they did not develop bleeding and (2) eligible participants who have not consented to take part in the main study but have consented to the collection of de-identified routine data.

Randomisation process {#Sec12}
---------------------

The pragmatic nature of the study means that the decision whether to administer the intervention will be based on clinicians' judgement, so that when a patient is actively bleeding within 24 h of surgery and a clinician has decided that FFP is needed to treat the bleeding, the patient will be randomised by the transfusion laboratory to either a single dose of FFP (fresh frozen plasma or octaplasLG) or 4-factor PCC (octaplex; Octapharma) using a web-based electronic database. Block randomisation will be used to ensure balance of treatments. The algorithm will be written by the study statistician using the ralloc command in Stata software (StataCorp, College Station, TX, USA), and a randomisation list will be produced. In the United Kingdom it is recommended that, as a variant Creutzfeldt-Jakob disease risk reduction measure, individuals born after 1 January 1996 should be transfused non-UK plasma, and this has been the practice since 1999 \[[@CR7]\]. At the study site, octaplasLG is the standard of care for management of such patients who are bleeding. Doses of intervention will be calculated according to subject weight and as per the dosing schedules below. Subject weightFFP or octaplasLG ≤  60 kg 3 units 61--90 kg 4 units \>  90 kg 5 unitsSubject weightoctaplex (IU) ≤  60 kg 500 (one vial) 61--90 kg 1000 (two vials) \>  90 kg 1500 (three vials)

If the subject continues to bleed after this first single dose of study treatment, standard care for the treatment of bleeding will continue as per hospital protocol, and this may include having additional FFP. However, no further PCC will be administered to these subjects.

### Study assessments {#Sec13}

Subjects will have laboratory assessments with standard routine care tests and thromboelastography. Research blood samples will also be taken at three time points (pre-intervention and 1 h and 24 h post-intervention) to perform a more detailed analysis of haemostatic capacity of subjects (see Table 1 in [Appendix](#Sec18){ref-type="sec"}, Additional file [1](#MOESM1){ref-type="media"}). Samples will be stored at − 70 °C ± 10 °C within 4 h of collection until they have been analysed, and no longer than 3 years after their collection. After analysis all samples will be destroyed. Samples will also be destroyed if the participant withdraws consent. Table 1Assessments of randomised subjectsStudy ProcedureScreening pre-operativelyPrior to surgery (time 0)Prior to randomisation -- intervention1 h post-study intervention24 h post-surgeryDays 7, 14, 21Day 30 (discharge/death)Day 90 (discharge/death)Visit windows− 14 daysDay 0Day 0Day 0Day 1+/− 1 day+/− 2 days+/− 7 daysScreening - assess eligibility (includes urine pregnancy test)XInformed consentXPatient characteristicsXAssessment by surgical teamXAssessment by anaesthesiologistXBlood tests^a^ -- FBCXXXXBlood tests^a^ - group and screen samplesXXBlood tests^a^ -- liver and renal function testsXXRoutine coagulation tests (PT, aPTT and fibrinogen)^a^XXXXAdditional clotting assays^b^XXXThromboelastographic assessment^a^XXXInform transfusion laboratory of need for FFPXRandomisation and intervention -- PCC or octaplasLG /FFPXTime of intervention (start and stop)XWeekly ICU assessmentXXThromboembolic AE/SAEXXXXXTransfusion AE/SAEXXXXHospital re-admission since dischargeXQuality of life -- EQ-5DXX90-Day survival status - end of study form (telephone or clinic visit)X*Abbreviations: AE* adverse events, *aPTT* activated partial thromboplastin time, *EQ-5D* EuroQol 5-dimension quality of life scale, *FBC* full blood count, *FFP* fresh frozen plasma, *ICU* intensive care unit, *PCC* prothrombin complex concentrate, *PT* prothrombin time, *SAE* serious adverse events

Clinical data that will be collected include age, sex, ethnicity, previous medical history, drug history, type of surgery and date/time of intervention. For those who have received intervention, daily and weekly (24 h and 7, 14, 21 and 30 days, or upon discharge, or death, whichever is first) assessments will be performed for amount of blood lost through the chest drains, blood components transfused (red blood cells, FFP, platelets and cryoprecipitate), any other haemostatic agents administered (such as recombinant factor VIIa, fibrinogen concentrate), total days in intensive care unit (level 3), high-dependency units (level 2), any organ failure (e.g., acute lung injury, acute respiratory distress syndrome, renal failure, liver failure), thrombosis (arterial and venous thrombosis), acute transfusion reaction, infections, duration of organ support (i.e., ventilatory support, cardiovascular support, and renal replacement therapy), and mortality. At 90 days or death, whichever is first, the following data will be collected: mortality, re-hospitalisation, thromboembolic event (arterial and venous), number of days alive and out of hospital since operation, and quality-of-life questionnaire.

Statistics {#Sec14}
----------

### Sample size calculation {#Sec15}

Over a 15-month period, we expect 638 patients to be eligible. This would allow us to estimate a consent rate of 30% within a 95% confidence interval of ± 3.5%. Assuming that 30% of the eligible patients consent, we will have a sample of 191 patients on the basis of which to estimate the proportion of consented patients who bleed and are administered FFP/PCC. From the national and local cardiac audit data, the rate of FFP transfusion in the eligible study patients is just over 30%, so we have estimated that 30% of consented patients will go on to develop bleeding during surgery that requires FFP transfusion. A sample size of 191 would allow us to estimate a proportion of 30% within a 95% confidence interval of ± 6.5%. On the basis of the above 30% rate, around 57 patients would be randomised within 15 months, giving an expected final sample size of 50 patients completing the study after allowing for 10% drop-out or loss to follow-up. This sample would be analysed for assessment of the secondary endpoints. No formal interim analysis for efficacy is planned. Numbers recruited, eligibility and consent rates will be considered by the data and safety monitoring committee (DSMC). Safety analysis including reporting of adverse events will be undertaken biannually for review by the DSMC. Other interim analysis may be undertaken at the request of the DSMC. Tables will be prepared by the study statistician.

The primary analysis will use data from the eligible patient population (for consent rate estimation) and the consenting patients (for estimation of the percentage who are randomised and receive study treatment). The proportion of patients who agree to collection of their de-identified data for up to 24 h after surgery will be obtained to analyse the population of eligible patients who do not consent to enter the main trial. The intention-to-treat population will be used to analyse secondary endpoints relating to the delivery of the intervention, clinical outcome data and haemostatic capacity of patients. Full details of the statistical considerations are given in the study statistical analysis plan.

Discussion {#Sec16}
==========

There has been no RCT that has compared the clinical efficacy and safety of PCC versus FFP in patients undergoing cardiac surgery who are bleeding and have not been taking a vitamin K antagonist in the peri-operative phase. Observational studies have suggested that PCC is safe in this setting; however, clinical equipoise and the lack of high-quality evidence mean that a large RCT is required to determine how PCC compares with FFP. Prior to such a trial, it is important to assess the feasibility of recruitment and different aspects of delivering the large trial, and this is the aim of this pragmatic, pilot RCT.

The pragmatic nature of the study means that the decision whether to administer the intervention will be based on 'real-world' practice rather than on a specific algorithm. One reason for choosing this approach is that it is vital that the results produced from the study are applicable to everyday practice in the future. Further, a recent phase III RCT in a cardiac surgery setting that compared fibrinogen concentrate with placebo highlighted some of the challenges with trials using complex algorithms to administer intervention \[[@CR8]\]. Difficulties in implementing such algorithms during trials can result in a number of shortcomings, such as low proportion of patients being actually randomised, high rate of non-adherence to the study protocol, high proportion of patients being given the intervention when they did not fulfil the study criteria, and consequently greater costs incurred.

Furthermore, the pragmatic nature of the trial reflects real-world current practice and does not add pre-intervention tests that could delay the issuing of FFP or PCC in a clinical scenario that requires rapid action. The pilot study will collect pre-intervention clotting profile data, but these data will not be used as entry criteria to allow the intervention to take place. There is no current bedside test with 100% sensitivity and specificity to identify the need for blood products after cardiac surgery, and as such the trial reflects real-world practice and current clinical judgement. There is no set limit for the amount of blood loss to define bleeding, because although this is possible with a closed chest and chest drains in an intensive care unit, it is not possible to define in the operating room before chest closure when swabs and suction are being used.

Another important aspect of this pilot trial are the surveys with different experts across disciplines (e.g., cardiac surgeons, anaesthetists, intensivists, transfusion laboratory scientists) and patient and public groups to reach a consensus on the outcome measures for the large trial. In 2015 Benstoem and colleagues \[[@CR9]\] performed a systematic review of the literature to identify the main outcomes that have been measured in cardiac surgery intervention trials in adults; in this review a total of 121 outcomes were identified, which were collapsed into 36 outcome domains. Using the results of the above review, in 2017 Benstoem and colleagues \[[@CR10]\] performed an international three-round eDelphi exercise to reach a consensus on core outcome sets that should be measured and reported, at minimum, in clinical trials of cardiac surgery. Of the 36 outcome variables identified from the systematic review, the panel reached consensus on four core outcome sets, which were mortality, quality of life, hospitalisation and cerebrovascular complications*.* Currently in the United Kingdom a national database is used to collect clinical outcomes of patients who have undergone cardiac surgery, and of the 4 core outcome sets agreed in the Delphi consensus \[[@CR10]\], quality of life is the only outcome that is not collected by the national database, and of the 36 outcome variables identified from the systematic review \[[@CR9]\], a total of 7 variables are collected in the United Kingdom. In order to obtain patient and public opinion about the outcome measures for the large trial, we will conduct surveys with patients and UK healthcare professionals, using the results of the above Delphi survey and the outcomes measured by the national database. Further, we will also conduct interviews with patients and clinicians who have been involved with the study to explore understanding of, and experience with, the intervention delivered to get their input on how best to optimise recruitment of participants and how to improve adherence of the trial protocols. All of these efforts will allow for a more cost-effective and informative trial in the future.

Trial status {#Sec17}
============

Protocol V2.0, 27 November 2018. Start date of subject recruitment: 1 March 2019. Project recruitment completion date: 30 June 2020.

The study was peer-reviewed by three independent experts as part of the BHF funding application and underwent Barts Heart Centre independent peer review. The study protocol has been reviewed by the Barts Cardiovascular Clinical Trials Unit (CVCTU) Scientific Committee and the Blizard Institute, Medicines and Healthcare products Regulatory Agency (MHRA) and NHS research ethics committees.

CVCTU will oversee the management and conduct of the trial and will be responsible for pharmacovigilance and safety reporting, coordination of trial committees, statistical analysis and reporting, and database management and case report form (CRF) design. The study sponsor will be responsible for trial monitoring. When the research trial is complete, it is a sponsor requirement that the records be kept for a further 20 years in a secure, long-term storage facility as per the sponsor policy.

Data will be captured in REDCap, a web-based electronic database, for all study participants, and the database will be held on a secure server at Queen Mary University of London (QMUL). Participants eligible for the study will be given a screening number, and this number will be used to identify them throughout the study duration. The screening number will be identified on all electronic case report forms (eCRFs) and study documentation (e.g., questionnaires, laboratory reports, enrolment and dispensing logs). Only authorised users approved by the chief investigator (CI) will have access to the REDCap electronic database, and each user will be assigned specific user roles and rights. Sponsor representatives and CVCTU team members will have read-only access to the data. The study research nurse will be the primary person with delegated responsibility for data entry and CRF completion. The transfusion laboratory team will have access to the eCRF to complete randomisation. The CI will have overall responsibility for data captured in the eCRF and be able to review, lock and electronically sign the completed eCRFs.

Supplementary information {#Sec19}
-------------------------

**Additional file 1.** SPIRIT 2013 Checklist.

Appendix {#Sec18}
========

AE

:   Adverse events

aPTT

:   Activated partial thromboplastin time

CI

:   Chief investigator

CRF

:   Case report form

CVCTU

:   Cardiovascular Clinical Trials Unit

DSMC

:   Data and safety monitoring committee

EQ-5D

:   EuroQol 5-dimension quality of life scale

FBC

:   Full blood count

FFP

:   Fresh frozen plasma

ICU

:   Intensive care unit

IgA

:   Immunoglobulin A

MHRA

:   Medicines and Healthcare products Regulatory Agency

PCC

:   Prothrombin complex concentrate

PROPHESY

:   Trial of PCC Versus FFP in Patients Undergoing Heart Surgery

PT

:   Prothrombin time

QMUL

:   Queen Mary University of London

RCT

:   Randomised controlled trial

SAE

:   Serious adverse events

TSC

:   Trial steering committee
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We acknowledge the support of the Joint Research Management Office, Queen Mary University of London, as sponsor of the study. The sponsor's contacts are as follows: Joint Research Management Office, 5 Walden Street, London, E1 2EF, UK. Email: research.governance\@qmul.ac.uk.

The trial is managed and run by CVCTU at William Harvey Research Institute, QMUL, a UK Clinical Research Network-registered unit (4). The Barts CVCTU will be responsible for pharmacovigilance and safety reporting, coordination of trial committees, statistical analysis and reporting, and database management and CRF design. The study sponsor (QMUL) will be responsible for trial monitoring. When the research trial is complete, it is a sponsor requirement that the records be kept for a further 20 years in a secure, long-term storage facility as per the sponsor policy.

Trial committees have been established to oversee and monitor the trial conduct and patient safety.

The trial steering committee (TSC) is chaired by an independent cardiac surgeon (Justin Nowell, St. George's Hospital), with three other independent members (Dr Nick Fletcher, consultant anaesthetist, St. George's Hospital, UK; Dr. Nicola Curry, consultant haematologist, Oxford University Hospital NHS Trust, UK; and Steve Stevenson, lay representative). The TSC provides overall supervision of the trial and ensures that it is being conducted according to the protocol, good clinical practice and relevant regulations. This committee also monitors trial progress in relation to recruitment, data capture and completeness, protocol deviations, and subject withdrawals. The committee meets every 6 months.

The data and safety monitoring committee (DSMC) is chaired by an independent haematologist (Prof Mike Laffan, Imperial College London, UK) with an independent anaesthetist (Dr Paul Diprose, University of Southampton, UK) and statistician (Dr Phil Edwards, London School of Hygiene and Tropical Medicine, UK). The DSMC is responsible for reviewing the trial data throughout the study and assessing whether there are any safety issues that need to be brought to the attention of the TSC or if there are any ethical reasons why the trial should not continue.

Study data are collected and managed using REDCap (research electronic data capture) tools \[[@CR11]\] hosted at Barts Cancer Centre, QMUL. REDCap is a secure, web-based application designed to support data capture for research studies, providing (1) an intuitive interface for validated data entry, (2) audit trails for tracking data manipulation and export procedures, (3) automated export procedures for seamless data downloads to common statistical packages, and (4) procedures for importing data from external sources \[[@CR11]\].

Internal audits will be performed by the sponsor throughout the study, and MHRA, which is independent from the investigators, and the sponsor may audit the study.
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The trial was granted clinical trial authorisation by the Medicines and Healthcare products Regulatory Authority (MHRA) and has received NHS research ethics approval from the London -- Fulham Research Ethics Committee (18/LO/1726) and Health Research Authority approval (IRAS no. 250632*)*. All subjects participating in the trial will provide written informed consent.

All relevant data from this study will be submitted to peer-reviewed journals for publication following the termination of the study and in line with sponsor trust publication policy. Data will be captured for all study participants, and no patient identifiable data will be used in any publications. The sponsor retains the right to review all publications prior to submission or publication. Responsibility for ensuring accuracy of any publication from this study is delegated to the CI.
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